← К результатам

BMC Musculoskelet Disord · 2021

Applications of CRISPR/Cas9 in the research of malignant musculoskeletal tumors.

BMC musculoskeletal disorders, 22(1): 149 PMID 33546657 DOI 10.1186/s12891-021-04020-2

Открыть в PubMed ↗ Открыть по DOI ↗

Аннотация

BACKGROUNDMalignant tumors of the musculoskeletal system, especially osteosarcoma, Ewing sarcoma and rhabdomyosarcoma, pose a major threat to the lives and health of adolescents and children. Current treatments for musculoskeletal tumors mainly include surgery, chemotherapy, and radiotherapy. The problems of chemotherapy resistance, poor long-term outcome of radiotherapy, and the inherent toxicity and side effects of chemical drugs make it extremely urgent to seek new treatment strategies.

MAIN TEXTAs a potent gene editing tool, the rapid development of CRISPR/Cas9 technology in recent years has prompted scientists to apply it to the study of musculoskeletal tumors. This review summarizes the application of CRISPR/Cas9 technology for the treatment of malignant musculoskeletal tumors, focusing on its essential role in the field of basic research.

CONCLUSIONCRISPR, has demonstrated strong efficacy in targeting tumor-related genes, and its future application in the clinical treatment of musculoskeletal tumors is promising.

Цитирование